# Viridian Therapeutics Posts $24.7 Million in Lumvoa Net Product Revenue for Q3 2026

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/48967
Published: 2026-11-05T02:33:04.000Z
Updated: 2026-11-05T02:33:04.000Z
Section: Business

> Total revenue was $25.752 million, and GAAP net loss per share was $0.81 on both basic and diluted bases.

Viridian Therapeutics generated $24.7 million in Lumvoa net product revenue during the third quarter of 2026, while total revenue reached $25.752 million for the period ended Sept. 30.

Net loss per common share was $0.81 on both basic and diluted bases. The results were released Nov. 4 and covered the three months ended Sept. 30, 2026.